This statistic depicts the projected savings in spending on originator biologics in the U.S. as of 2018. The projections are provided by different agencies for several time ranges. According to the projection by ESI (Express Scripts, Inc.), some 250 billion U.S. dollars will be saved due to the use of biosimilars in the United States between 2014 and 2024.
Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018
(in billion U.S. dollars)
CBO = Congressional Budget Office;
RAND = RAND Corporation;
QI = QuintilesIMS (IQVIA);
ESI = Express Scripts Inc.
* Actually, the RAND gives a range of 40-93 billion U.S. dollars.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Association for Accessible Medicines, & IQVIA. (February 13, 2018). Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars) [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/869818/spending-on-originator-biologics-projections/
Association for Accessible Medicines, und IQVIA. "Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)." Chart. February 13, 2018. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/869818/spending-on-originator-biologics-projections/
Association for Accessible Medicines, IQVIA. (2018). Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/869818/spending-on-originator-biologics-projections/
Association for Accessible Medicines, and IQVIA. "Projected Reduction in U.S. Biosimilar Direct Spending on Originator Biologics as of 2018 (in Billion U.S. Dollars)." Statista, Statista Inc., 13 Feb 2018, https://www-statista-com.ezproxy.canberra.edu.au/statistics/869818/spending-on-originator-biologics-projections/
Association for Accessible Medicines & IQVIA, Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars) Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/869818/spending-on-originator-biologics-projections/ (last visited November 10, 2024)
Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars) [Graph], Association for Accessible Medicines, & IQVIA, February 13, 2018. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/869818/spending-on-originator-biologics-projections/
